BBIO Stock Analysis: Buy, Sell, or Hold?
BBIO - BridgeBio Pharma, Inc. Common Stock
$82.94
-2.95 (-3.43%)
▼
5d:
+6.68%
30d:
+23.05%
90d:
+11.19%
HOLD
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When BBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called BBIO this week
67% bullish • 3 bearish
67% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: BBIO is 7.3% above its trading range ($77.29). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: BBIO is 7.3% above its trading range ($77.29). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.02
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$11.81
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BBIO is currently trading at $82.94, which is considered extended relative to its 30-day fair value range of $64.85 to $77.29. From a valuation perspective, the stock is trading at a discount (Forward PE: 158.2) compared to its historical average (208.1). Remarkably, the market is currently pricing in an annual earnings decline of 8.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BBIO is in a strong uptrend. Immediate support is located at $68.82, while resistance sits at $93.42. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: BBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $102.47 (+19.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BBIO is in a strong uptrend. Immediate support is located at $68.82, while resistance sits at $93.42. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: BBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $102.47 (+19.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$64.85 -
$77.29
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
BBIO is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading below Wall St target ($102.47)
Trading Range Analysis
30-Day Trading Range
$64.85 -
$77.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$68.82
Resistance Level
$93.42
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
158.18
Wall Street Target
$102.47
(+19.3%)
Revenue Growth (YoY)
66.8%
Profit Margin
-124.4%
Valuation Discount vs History
-8.7% cheaper
PE vs Historical
158.2 vs 208.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.7%
(market-implied from PE analysis)
1-Year Target
$78.42
(-9%)
2-Year Target
$71.60
(-17%)
3-Year Target
$65.37
(-24%)
3-Yr Target (if PE normalizes)
(PE: 158→208)
$86.00
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 158.2 to 208.1
Stabilization Target:
$113.00
(+31.6%)
PE Expansion Potential:
+31.6%
Share & Embed Analysis
Last updated: July 13, 2026 11:18 AM ET
Data refreshes hourly during market hours. Next update: 12:18 PM
Data refreshes hourly during market hours. Next update: 12:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBIO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Neil Kumar
SELL
40000 shares
2026-04-09
Gilbert Ray Cisneros, Jr.
BUY
2026-03-19
Gilbert Ray Cisneros, Jr.
BUY
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 63 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 62 BUY |
Advanced BBIO Option Strategies
Professional options setups generated by AI based on today's BBIO price and gamma walls.
